Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
US6888027 | ACROTECH BIOPHARMA | Carbamic acid compounds comprising a sulfonamide linkage as HDAC inhibitors |
Aug, 2026
(2 years from now) | |
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US8835501 | ACROTECH BIOPHARMA | Pharmaceutical formulations of HDAC inhibitors |
Oct, 2027
(3 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
Orphan Drug Exclusivity(ODE) | Jul 03, 2021 |
New Chemical Entity Exclusivity(NCE) | Jul 03, 2019 |
Orphan Drug Exclusivity(ODE-68) | Jul 03, 2021 |
Drugs and Companies using BELINOSTAT ingredient
NCE-1 date: 03 July, 2018
Market Authorisation Date: 03 July, 2014
Treatment: Treatment of patients with relapsed or refractory peripheral t-cell lymphoma (ptcl).
Dosage: POWDER;INTRAVENOUS
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US8410077 | ACROTECH BIOPHARMA | Sulfoalkyl ether cyclodextrin compositions |
Mar, 2029
(4 years from now) | |
US9200088 | ACROTECH BIOPHARMA | Sulfoalkyl ether cyclodextrin compositions |
Mar, 2029
(4 years from now) | |
US11020363 | ACROTECH BIOPHARMA | Injectable nitrogen mustard compositions comprising a cyclodextrin derivative and methods of making and using the same |
May, 2030
(6 years from now) | |
US10864183 | ACROTECH BIOPHARMA | Injectable nitrogen mustard compositions comprising a cyclodextrin derivative and methods of making and using the same |
May, 2030
(6 years from now) | |
US10940128 | ACROTECH BIOPHARMA | Injectable melphalan compositions comprising a cyclodextrin derivative and methods of making and using the same |
Jun, 2030
(6 years from now) | |
US9493582 | ACROTECH BIOPHARMA | Alkylated cyclodextrin compositions and processes for preparing and using the same |
Feb, 2033
(8 years from now) | |
US10040872 | ACROTECH BIOPHARMA | Alkylated cyclodextrin compositions and processes for preparing and using the same |
Jan, 2034
(9 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
Orphan Drug Exclusivity(ODE) | Mar 10, 2023 |
Orphan Drug Exclusivity(ODE-110) | Mar 10, 2023 |
Drugs and Companies using MELPHALAN HYDROCHLORIDE ingredient
Market Authorisation Date: 10 March, 2016
Treatment: For high-dose conditioning treatment prior to hematopoietic progenitor (stem) cell transplantation in patients with multiple myeloma
Dosage: POWDER;INTRAVENOUS
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
US6028071 | ACROTECH BIOPHARMA | Purified compositions of 10-propargyl-10-deazaaminopterin and methods of using same in the treatment of tumors |
Jul, 2022
(1 year, 9 months ago) | |
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US7622470 | ACROTECH BIOPHARMA | Treatment of T-cell lymphoma using 10-propargyl-10-deazaaminopterin |
May, 2025
(1 year, 1 month from now) | |
US8299078 | ACROTECH BIOPHARMA | Treatment of T-cell lymphoma using 10-propargyl-10-deazaaminopterin |
May, 2025
(1 year, 1 month from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
Orphan Drug Exclusivity(ODE) | Sep 24, 2016 |
New Chemical Entity Exclusivity(NCE) | Sep 24, 2014 |
Drugs and Companies using PRALATREXATE ingredient
NCE-1 date: 24 September, 2013
Market Authorisation Date: 24 September, 2009
Treatment: Treatment of patients with relapsed or refractory peripheral t-cell lymphoma
Dosage: SOLUTION;INTRAVENOUS
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
US6500829 | ACROTECH BIOPHARMA | Substantially pure diastereoisomers of tetrahydrofolate derivatives |
Mar, 2022
(2 years ago) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
Orphan Drug Exclusivity(ODE-10) | Apr 29, 2018 |
Orphan Drug Exclusivity(ODE) | Mar 07, 2015 |
New Indication(I-637) | Apr 29, 2014 |
Drugs and Companies using LEVOLEUCOVORIN CALCIUM ingredient
Market Authorisation Date: 07 March, 2008
Treatment: NA
Dosage: POWDER;INTRAVENOUS; SOLUTION;INTRAVENOUS
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US11541012 | ACROTECH BIOPHARMA | Compositions comprising disodium levofolinate |
Mar, 2039
(14 years from now) |
Drugs and Companies using LEVOLEUCOVORIN ingredient
Market Authorisation Date: 19 October, 2018
Treatment: NA
Dosage: POWDER;INTRAVENOUS